Short answer
Vera Therapeutics, Inc. (VERA) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Third-quarter results for period ended September 30, 2026, announced November 5, 2026.
Vera Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Third-quarter results for period ended September 30, 2026, announced November 5, 2026
- Corporate updates included alongside financial results
- Detailed financial figures and operating developments available in Exhibit 99.1 press release
Item EX-99.1 · Exhibit EX-99.1
- Q3 launch generated $10.3M product revenue and approximately 700 Patient Start Forms, establishing initial commercial traction for TRUTAKNA
- ORIGIN 3 showed eGFR decline of 0.6 versus 5.6 mL/min/1.73m²/year placebo, a 5.0 treatment difference and p<0.0001
- sBLA submitted November 3 for full IgAN approval, with potential FDA decision expected mid-2027
- Net loss widened to $93.7M, or $1.30 per share, as SG&A increased to $61.4M for commercialization
- Cash and securities totaled $384.0M, with $75M drawn in October and up to $350M remaining under the debt facility
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Vera Therapeutics, Inc. 8-K filings
Get the next VERA 8-K as it lands
Follow VERA for push alerts, or ask the research agent what this filing means.